alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
10430.

#### King *v.*The State.

Stephens, J.

1. While the defendant in a criminal case may make to the jury a statement in his own behalf not under oath, -which may be received in whole-or in part by the jury in preference to the sworn testimony, he is not a competent witness in the case, and cannot be sworn as such. While he may be cross-examined not under oath, if he consents thereto, an offer by his counsel to put him under oath and permit him to be cross-examined was properly rejected by the trial judge.

*50Decided June 27, 1919.

Accusation of violating prohibition law; from city court of Macon—Judge Guerry. March 1, 1919.

*Hubert F. Rawls, Olm J. Wimberly, Thomas Arnold Jacobs Jr.,*for plaintiff in error.

*Will Gunn, solicitor,*contra. •

'2. The evidence offered by counsel for defendant as set out in the second ground of the amendment to the motion for new trial was entirely irrelevant to the issue and it was not error on the part of the trial judge to refuse to admit the same.

3. The assignment of error set out in the third ground of the amendment to the motion for new trial, not being referred to in the brief of counsel for the plaintiff in error, will be treated as abandoned.

4. The evidence is sufficient to support the verdict, which has the approval of the trial judge, and this court will not interfere therewith.

*Judgment affirmed.*

*Broyles, P. J., and Bloodioorth, J., concur.*
**Exhibit 32**

 

PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

I, the CorporateTrustee of Mesabi Trust, certify, pursuant to 18 U.S.C. Section 1350, asadopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that,to the best of my knowledge, the Annual Report of Mesabi Trust on Form 10-K forthe fiscal year ended January 31, 2004 fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of1934, as amended, and that information contained in such Form 10-K fairlypresents in all material respects the financial condition and results ofoperations of Mesabi Trust.

 

 
| /s/ Rodney Gaughan                   |   | April 19, 2004 |
|--------------------------------------|--------|---------------------|
| Rodney Gaughan*                      |   |
| Assistant Vice President             |   |
| Deutsche Bank Trust Company Americas |   |

 

----

* There are noprincipal executive officers or principal financial officers of the registrant.

 

*Asigned original of this written statement required by Section 906 has beenprovided to Mesabi Trust and will be retained by Mesabi Trust and furnished tothe Securities and Exchange Commission or its staff upon request.*

 

----
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

Part A, Office of the Secretary, Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (HHS) is being amended at Chapter AN, Office of the Assistant Secretary for Preparedness and Response (ASPR), as last amended at 78 FR 25277 April 30, 2013. This organizational change is to realign the Medical Reserve Corps from the HHS Office of the Assistant Secretary of Health to ASPR under the Office of Emergency Management and is consistent with authorities established under Sections 1703, 2811(c)(2)(D), and 2813 of the Public Health Service Act, as modified by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5). The change is as follows.

I. Under Part A, Chapter AN, Section AN.00, Mission, add “Authority over and responsibility for the Medical Reserve Corps.”

II. Delegations of Authority. All delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegation, provided they are consistent with this reorganization.

                    This reorganization is effective on the date of publication in the                     **Federal Register**                    .                

Dated: November 19, 2014.

Sylvia M. Burwell,

Secretary.

[FR Doc. 2014-28030 Filed 11-25-14; 8:45 am]

BILLING CODE 4150-28-P
Exhibit 32.1

                            CERTIFICATION PURSUANT TO
                       18 UNITED STATES CODE SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Gregory F. Kowal, Chief Executive Officer of Mera Pharmaceuticals, certify
that (1) Mera Pharmaceuticals, Inc.'s Form 10-QSB for the quarter ended January
31, 2006 fully complies with the requirements of Section 3 (a) or 15 (d) of the
Securities Exchange Act of 1934 and (ii) the information contained in the Form
10-QSB for the quarter ended January 31, 2006 fairly presents, in all material
respects, the financial condition and the results of operations of Mera
Pharmaceuticals, Inc.

Date:   March 13, 2006

/s/Gregory F. Kowal
----------------------------------------
Gregory F. Kowal
Chief Executive Officer

A signed original of this written statement required by Section 906 has been
provided to Mera Pharmaceuticals, Inc. and will be retained by Mera
Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or
its staff upon request.
#### TOMPKINS *v.*THE STATE.

Refusal to continue the ease because of the absence of leading counsel can not in this case be held to have been an abuse of discretion.

The evidence authorized the conviction of the accused.

Decided October 10, 1919.

Accusation of possession of intoxicating liquor; from city court of Wrightsville—Judge Blount. April 24, 1919.

*B. T. Rawlings, B. E. Moye,*for plaintiff in error.

*O. S. Glaxton, solicitor,*contra.

Bloodworth, J.

1. There is no merit in either of the two motions to dismiss the bill of exceptions.

2. In the motion for a new trial it is alleged that the court erred in refusing to continue the case on account of the absence of leading counsel for the defendant. To the motion for a new trial the trial judge attached the following note: “This ease had been continued several times at the instance of defendant’s side. At the November term, 1918, the defendant and one of his counsel, Judge Rawlings, were absent, and the bond of defendant was forfeited. On February 10, 1919, about 10 o’clock, a. m., the time this ease was set for trial, the same was called, and the motion for continuance made on account of the absence of Judge Rawlings; the same was then set for 1.30 o’clock, to give defendant an opportunity to communicate with and have Judge Rawlings present. At the time set no showing was made that any effort had been *265made by defendant to procure the presence of Judge Rawlings, and the case proceeded to trial.” When considered in the light of the above qualifying note, and the counter-showing made by the State at the hearing of the motion for a new trial, this court cannot say, as a matter of law, that the judge abused his discretion in refusing to further continue the case.

3. “Where there is some evidence from which the guilt of one accused of crime can be legitimately inferred, it is entirely within the province of the jury to draw that inference.”

*Judgment affirmed.*

*Broyles, O. J., and Luhe, J., concur.*
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                      24,162,161
<INT-BEARING-DEPOSITS>                         100,000
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                227,372,262
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                    812,458,855
<ALLOWANCE>                                 11,588,649
<TOTAL-ASSETS>                           1,078,266,409
<DEPOSITS>                                 840,935,077
<SHORT-TERM>                               134,101,643
<LIABILITIES-OTHER>                         13,088,321
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     1,177,619
<OTHER-SE>                                  88,963,749
<TOTAL-LIABILITIES-AND-EQUITY>           1,078,266,409
<INTEREST-LOAN>                             31,924,546
<INTEREST-INVEST>                            7,168,457
<INTEREST-OTHER>                                40,443
<INTEREST-TOTAL>                            39,133,446
<INTEREST-DEPOSIT>                          19,577,651
<INTEREST-EXPENSE>                          22,581,332
<INTEREST-INCOME-NET>                       16,552,114
<LOAN-LOSSES>                                1,120,000
<SECURITIES-GAINS>                               1,615
<EXPENSE-OTHER>                              8,057,390
<INCOME-PRETAX>                              8,479,918
<INCOME-PRE-EXTRAORDINARY>                   8,479,918
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 5,635,918
<EPS-BASIC>                                        .80
<EPS-DILUTED>                                      .77
<YIELD-ACTUAL>                                    3.43
<LOANS-NON>                                          0
<LOANS-PAST>                                    12,000
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                            10,448,496
<CHARGE-OFFS>                                      188
<RECOVERIES>                                    20,341
<ALLOWANCE-CLOSE>                           11,588,649
<ALLOWANCE-DOMESTIC>                        10,538,426
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                      1,050,223


</TABLE>
[Federal Register Volume 79, Number 228 (Wednesday, November 26, 2014)]
[Notices]
[Page 70555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-27986]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Sematech, Inc. D/B/A International Sematech

    Notice is hereby given that, on October 30, 2014, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Sematech, Inc. d/b/a 
International Sematech (``SEMATECH'') has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing changes in its membership. The notifications were 
filed for the purpose of extending the Act's provisions limiting the 
recovery of antitrust plaintiffs to actual damages under specified 
circumstances. Specifically, TowerJazz Panasonic Semiconductor Co., 
Ltd., Uozo City, JAPAN, has been added as a party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and SEMATECH intends to file additional 
written notifications disclosing all changes in membership.
    On April 22, 1988, SEMATECH filed its original notification 
pursuant to Section 6(a) of the Act. The Department of Justice 
published a notice in the Federal Register pursuant to Section 6(b) of 
the Act on May 19, 1988 (53 FR 17987).
    The last notification was filed with the Department on August 1, 
2014. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on September 3, 2014 (79 FR 52364).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2014-27986 Filed 11-25-14; 8:45 am]
BILLING CODE 4410-11-P
<PAGE>   1
                                                                    EXHIBIT 23.2


                   CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS


     As independent public accountants, we hereby consent to the incorporation
of our report dated October 11, 1996, included in this Form 10-K of
International Home Foods, Inc. (the Company) for the year ended December 31,
1997, into the Company's previously filed Registration Statement File No.
333-43297.


Arthur Andersen LLP
New York, New York
March 30, 1998
<PAGE>

                                                                    EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350

          In connection with the Annual Report of Mills Music Trust. (the
"Trust") on Form 10-K for the fiscal year ended December 31, 2004, as filed with
the Securities and Exchange Commission (the "Report"), I, Marcia Markowski, the
Trust officer of the corporate trustee, certify, pursuant to 18 U.S.C. Section
1350, that to my knowledge:

          1. The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

          2. The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Trust.*

*    The statements of cash receipts and disbursements reflect only cash
     transactions and do not include transactions that would be recorded in
     financial statements presented on the accrual basis of accounting. The
     Trust is required to distribute all funds received after payment of
     expenses. Accordingly, the Trust has not prepared any statements of
     financial condition or cash flows.


Date: April 12, 2006                    /s/ Marcia Markowski
                                        ----------------------------------------
I 

108TH CONGRESS 

2D SESSION H. R. 4402

To suspend temporarily the duty on 2-Naphthalenesulfonic acid, 6-[(2,4-

diaminophenyl)azo]-3-[[4-[[4-[[7-[(2,4-diaminophenyl azo]-1-hydroxy-3-

sulfo-2-naphthalenyl]azo]phenyl]amino]-3- sulfophenyl]azo]-4-hydroxy-, 

trisodium salt. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 19, 2004

Mrs. MYRICK introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL

To suspend temporarily the duty on 2-Naphthalenesulfonic 

acid, 6-[(2,4-diaminophenyl)azo]-3-[[4-[[4-[[7-[(2,4-

diaminophenyl azo]-1-hydroxy-3-sulfo-2-

naphthalenyl]azo]phenyl]amino]-3- sulfophenyl]azo]-4-hydroxy-, trisodium salt.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. TEMPORARY SUSPENSION OF DUTY. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading:
2

•HR 4402 IH 

‘‘ 9902.01.02 2-Naphthalenesulfonic acid, 

6-[(2,4-diaminophenyl)azo]-

3-[[4-[[4-[[7-[(2,4-

diaminophenyl)azo]-1-hydroxy-3-sulfo-2-

naphthalenyl]azo]phenyl]amino]-3- 

sulfophenyl]azo]-4-hydroxy-, 

trisodium salt (CAS No. 

6473–13–8) (provided for in 

subheading 3204.14.50) ...... Free Free No change 12/31/07 ’’. 

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act.

Æ
10538.

#### Perdue & Pace *v.*Hurst.

Decided October 9, 1919.

Garnishment; from Haralson superior court—Judge Irwin. April 7, 1919.

*I. N. Cheney, Griffith & Matthews,*for plaintiffs in error.

*Edwards & Edwards,*contra.

Bloodworth, J.

1. The amendment to the motion for a no.w trial is too uncertain and indefinite to be considered by this court. It is not even stated at what time Hurst “had the deed in his possession.” The ground is not understandable without reference to other parts of the record, and it is a well-established rule that “each ground of the motion for new trial must be complete and understandable without resorting to an examination of the brief of the evidence or of any other part of the record.” *Morrow*v. *State,*22 *Ga. App.*253 (95 S. E. 934), and cases cited.

2. No error of law is pointed out, the verdict has the approval of the trial judge, there is some evidence authorizing the verdict, and, under repeated and uniform rulings of this court and of the Supreme Court, a reviewing court is powerless to interfere. *Bradham*v. *State,*21 *Ga. App.*510 (94 S. E. 618), and cases cited. '

*Judgment affirmed.*

*Broyles, G. J., and Luke, J., concur.*
10654.

#### Lemmons *v.*The State.

Decided October 10, 1919.

Conviction of manslaughter; from Fulton superior court—Judge Humphries. May 33, 1919.

*Harvey Hill, James E. Garst,*for plaintiff in error.

*John A. Boylcin, solicitor-general, E. A. Stephens,*contra.

Broyles, O. J.

The verdict was amply authorized by the evidence, and none of the grounds of the amendment to the motion for a new trial shows cause for setting it aside.

*Judgment affirmed.*

*Luke and Bloodworlh, JJ., concur.*
10630.

#### Wilder Manufacturing Company *v.*Elder.

Bloodworth, J.

A trial by jury was waived, and this case was submitted to one of the judges of the municipal court of Atlanta, and he passed upon the case without the intervention of a jury. There is a sharp *266conflict in the evidence. The judge who tried the case saw and heard the witnesses. The judge of the superior court overruled the petition for certiorari, thus approving the finding of the judge of the municipal court. We cannot say that the judge of the superior court erred in his ruling, and the judgment is

Decided October 10, 1919.

Certiorari; from Fulton superior court—Judge Bell. April 10, 1919.

*Little, Powell, Smith <& Goldstein,*for plaintiff in error.

*George Westmoreland, Bell & Bilis,*contra.

*Affirmed.*

*Broyles, O. J., and Luke, J., concur.*
[Federal Register Volume 79, Number 231 (Tuesday, December 2, 2014)]
[Notices]
[Page 71441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-28392]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: AIDS and AIDS Related Research.
    Date: December 16, 2014.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Robert Freund, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 5216, MSC 7852, Bethesda, MD 20892, 301-435-
1050, <a href="/cdn-cgi/l/email-protection#680e1a0d1d060c1a280b1b1a46060100460f071e"><span class="__cf_email__" data-cfemail="52342037273c3620123121207c3c3b3a7c353d24">[email protected]</span></a>.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: November 26, 2014.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-28392 Filed 12-1-14; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
No. 87-6378.

#### Reigh et al. *v.*Schleigh et al.

C. A. 4th Cir. Certiorari denied.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER>    1
       
<S>                                           <C>
<FISCAL-YEAR-END>                             Dec-31-1998
<PERIOD-START>                                Jan-01-1998
<PERIOD-END>                                  Sep-30-1998
<PERIOD-TYPE>                                       9-mos
<CASH>                                          1,010,135
<SECURITIES>                                            0
<RECEIVABLES>                                     195,189
<ALLOWANCES>                                            0
<INVENTORY>                                             0
<CURRENT-ASSETS>                                1,218,776
<PP&E>                                          9,573,979
<DEPRECIATION>                                  2,248,085
<TOTAL-ASSETS>                                  8,520,108
<CURRENT-LIABILITIES>                             561,257
<BONDS>                                         4,278,525
<PREFERRED-MANDATORY>                                   0
<PREFERRED>                                             0
<COMMON>                                                0
<OTHER-SE>                                      2,335,102
<TOTAL-LIABILITY-AND-EQUITY>                    8,520,108
<SALES>                                         1,191,233
<TOTAL-REVENUES>                                1,226,197
<CGS>                                                   0
<TOTAL-COSTS>                                     626,558
<OTHER-EXPENSES>                                  313,829
<LOSS-PROVISION>                                        0
<INTEREST-EXPENSE>                                274,628
<INCOME-PRETAX>                                    23,283
<INCOME-TAX>                                            0
<INCOME-CONTINUING>                                23,283
<DISCONTINUED>                                          0
<EXTRAORDINARY>                                         0
<CHANGES>                                               0
<NET-INCOME>                                       23,283
<EPS-PRIMARY>                                           0
<EPS-DILUTED>                                           0
        

</TABLE>